Abstract
Fluticasone propionate is approved for the long-term maintenance therapy of persistent asthma of all severities, and its safety and efficacy has been well established in clinical trials and practice. With the need to phase out chlorofluorocarbons (CFCs) as propellants in pressurized metered-dose inhalers (pMDIs), hydrofluoroalkane (HFA) propellants have been introduced as a safer, environmentally friendly alternative. A HFA formulation of fluticasone propionate has been developed as a microgram-equivalent replacement for the traditional CFC pMDI. Clinical trials have demonstrated that the fluticasone propionate HFA pMDI is an acceptable clinical alternative for the CFC pMDI with similar safety and efficacy.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.